

**F. No. 6/19/2026-DGTR
Government of India
Department of Commerce
Ministry of Commerce & Industry
(Directorate General of Trade Remedies)
4th Floor, Jeevan Tara Building
5, Parliament Street, New Delhi – 110001**

Date: 11th August, 2026

**Case No. : AD (OI) (17/2026)
SETU Case ID: AD/OI/019/2026**

To,

All interested parties

Subject: PUC/PCN methodology in the anti-dumping investigation concerning imports of “Dialyzers” originating in or exported from China and Malaysia.

1. Attention of all interested parties is invited to the above-mentioned investigation initiated vide Notification No.6/19/2026-DGTR dated 25th June 2026. The non-confidential version of the application filed by the domestic industry was made available to interested parties on the SETU platform.
2. Whereby, the interested parties were granted an opportunity to present their comments on the scope of the product under consideration (PUC), and product control number (PCN) methodology, within a period of 15 days from the date of intimation, which ended on 18th July 2026.
3. Certain interested parties have filed comments in regard to the scope of PUC and PCN methodology. Subsequent to the comments from the interested parties, the domestic industry has provided its submissions in response to the comments of the interested parties.
4. After due deliberation with the Interested Parties, Domestic Industry and considering the written submissions made by both the parties regarding scope of PUC along with facts and evidences available on record, the Authority has decided to adopt the same scope of product under consideration as notified in the initiation Notification No.6/19/2026-DGTR dated 25th June 2026 without any changes.
5. The product under consideration (hereinafter referred to as “PUC”) was defined as under:

“The product under consideration in the present application is “Dialyzers”. Dialyzer is a disposable medical device used in haemodialysis treatment. A dialyzer acts as an artificial kidney and performs the critical function of removing waste substances such as urea and creatinine, excess fluid, and toxins from a patient’s blood. It is a life-saving medical consumable and forms an indispensable part of the haemodialysis system.

It is an essential component of a dialysis machine and facilitates the

process of blood purification during dialysis treatment. The dialyzer works on the principle of diffusion and filtration through a semi-permeable hollow fibre membrane, whereby impurities in the blood pass into the dialysate are retained while blood cells and essential components are passed through the membrane. Dialyzers are available in different membrane surface areas and are also classified on the basis of membrane flux.

Dialyzers manufactured and exported by Fresenius bearing brand names as, F6 HPS, F7 HPS, FX5, FX8, FX10, FX60, FX80, HF60, HF80, are excluded from the scope of the investigation.”

6. Additionally, after examining the comments and submissions of the interested parties, the Authority considers the following PCN methodology for the purpose of the investigation:

Parameter	Specification	Code
Surface Area of Dialyzer	1.3 M ² and Below	X
	1.3 M ² and Below 1.8 M ²	Y
	1.8 M ² and Above	Z
Flux	High	H
	Other (Low and Mid)	M
Housing Material	Poly Carbonate	PC
	Poly Propylene	PP

7. The original last date of submission of questionnaire responses was 37 days from the date of intimation. However, due to the revision of the PUC/PCN, all interested parties are directed to file their questionnaire responses 15 days from the date of publication of this notice on the SETU portal.
8. This communication is limited to clarifying the scope of the product under consideration for which the present investigation is being conducted. This does not preclude interested parties from providing any additional and relevant information and evidence to substantiate their requests for exclusion for any particular product. The Authority shall decide the scope of the product under consideration for any measures recommended, after considering relevant information and evidence furnished by all interested parties during the course of the investigation.

This is issued with the approval of the Designated Authority.

Regards
Onkar Nath Mishra, I.E.S.
Assistant Director
Directorate General of Trade Remedies (DGTR)